Research Grade Anti-Human CD309/KDR/VEGFR-2 (IMC-1C11) (HW338013)

Datasheet Share product Copy info

Price(USD): $

Spec:

20ug
50ug
100ug
1mg

Number:

Overview
Images
References
Datasheet

Overview

Catalog No.

HW338013

Description

Anti-Human CD309/KDR/VEGFR-2 (IMC-1C11) (HW338013) is a research-grade recombinant antibody targeting CD309. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

Species reactivity

Human

Applications

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Host species

Chimeric

Isotype

IgG1

Clone ID

IMC-1C11

Expression system

Mammalian Cells

Clonality

Monoclonal

Target

FLK-1, Kinase insert domain receptor, VEGFR2, Fetal liver kinase 1, CD309, Vascular endothelial growth factor receptor 2, Protein-tyrosine kinase receptor flk-1, FLK1, VEGFR-2, KDR

Endotoxin level

Please contact the lab for this information.

Purity

>95% purity as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P35968

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:2000-1:20000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

Background

Vascular endothelial growth factor receptor 2 (CD309/VEGFR-2) is a ~151 kDa protein. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. CD309 is the therapeutic target of ramucirumab (Cyramza).

Note

For research use only. Not suitable for clinical or therapeutic use.

Images